Abstract: A machine can be accessed and controlled with the help of an interface device. The customizable interface device contains device elements that define features relating to the external representation and internal functionality of the interface device, as linked to one or more machines. An operator can use a configuration station to implement single or reoccurring queries that interact with the interface device and corresponding machines. In particular, the queries target the configuration of device elements in the interface device. The process can include temporarily unloading unused features from active memory and mirroring property changes initialized by a source. An emulator can assist in the configuration process by providing a preliminary software representation of the interface device hardware. A user can develop, test, and reconfigure functions on the emulator before loading the finalized platform to the interface device.

Abstract: A plurality of similar components for forming a plant covering device for the protection of plants from external adverse weather elements and other hazards. The components are made of a thin sheet of flexible plastic or other material cut into similar two-dimensional component panels allowing many different configurations to be made out of the plurality of components. The individual component panels are provided with a fastening means for joining the separate component panels into a completed assembly. The plant covering device provides an easily assembled, self-supporting structure to be placed over one or more plants or a location. The plant covering device is erected without the use of tools or need for a separate frame or support. The size of the plant covering device may be reconfigured and expanded in width, and/or height, and/or depth using an additional plurality of component panels. The plant covering device may be used with stakes or spikes.

Abstract: The present invention relates to compounds of formula I or formula Ia or pharmaceutically acceptable salts thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

Abstract: The present application describes macrocyclic compounds of formula (I) with NS3 protease inhibitory activity for treating hepatitis C virus infection.

Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

Abstract: A machine can be accessed and controlled with the help of an interface device. The customizable interface device contains device elements that define features relating to the external representation and internal functionality of the interface device, as linked to one or more machines. An operator can use a configuration station to implement single or reoccurring queries that interact with the interface device and corresponding machines. In particular, the queries target the configuration of device elements in the interface device. The process can include temporarily unloading unused features from active memory and mirroring property changes initialized by a source. An emulator can assist in the configuration process by providing a preliminary software representation of the interface device hardware. A user can develop, test, and reconfigure functions on the emulator before loading the finalized platform to the interface device.

Abstract: A machine can be accessed and controlled with the help of an interface device. The customizable interface device contains device elements that define features relating to the external representation and internal functionality of the interface device, as linked to one or more machines. An operator can use a configuration station to implement single or reoccurring queries that interact with the interface device and corresponding machines. In particular, the queries target the configuration of device elements in the interface device. The process can include temporarily unloading unused features from active memory and mirroring property changes initialized by a source. An emulator can assist in the configuration process by providing a preliminary software representation of the interface device hardware. A user can develop, test, and reconfigure functions on the emulator before loading the finalized platform to the interface device.

Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.

Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

Abstract: The present invention relates to compounds of formula I or formula Ia or pharmaceutically acceptable salts thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

Abstract: A fluid pump including provisions for cooling and/or flushing in the vicinity of a static seal. In one embodiment, the invention includes an open channel fluid passageway defined on a generally flat surface of a pump housing. A centrifugal rotor with a generally flat backplate rotates proximate a surface of the housing. The fluid passageways are adapted and configured to have a pathway that includes a directional component parallel to the direction of rotation, such that fluid drag from the rotating backplate induces flow within the passageway. The passages of the exit can be positioned such that flow exiting the passageway is at least partly tangential to the seal and/or the seal housing.

Abstract: A fluid pump including provisions for cooling and/or flushing in the vicinity of a static seal. In one embodiment, the invention includes an open channel fluid passageway defined on a generally flat surface of a pump housing. A centrifugal rotor with a generally flat backplate rotates proximate a surface of the housing. The fluid passageways are adapted and configured to have a pathway that includes a directional component parallel to the direction of rotation, such that fluid drag from the rotating backplate induces flow within the passageway. The passages of the exit can be positioned such that flow exiting the passageway is at least partly tangential to the seal and/or the seal housing.

Abstract: The present invention relates to inhibitors of aspartic proteinases, particularly, BACE. The present invention also relates to compositions thereof and methods therewith for inhibiting BACE activity in a mammal, and for treating Alzheimer's Disease and other BACE-mediated diseases.